| Year |
Citation |
Score |
| 2012 |
Yoder AR, Robinson JW, Dickey DM, Andersland J, Rose BA, Stone MD, Griffin TJ, Potter LR. A functional screen provides evidence for a conserved, regulatory, juxtamembrane phosphorylation site in guanylyl cyclase a and B. Plos One. 7: e36747. PMID 22590601 DOI: 10.1371/Journal.Pone.0036747 |
0.669 |
|
| 2010 |
Yoder AR, Stone MD, Griffin TJ, Potter LR. Mass spectrometric identification of phosphorylation sites in guanylyl cyclase A and B. Biochemistry. 49: 10137-45. PMID 20977274 DOI: 10.1021/Bi101700E |
0.624 |
|
| 2009 |
Dickey DM, Yoder AR, Potter LR. A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation. The Journal of Biological Chemistry. 284: 19196-202. PMID 19458086 DOI: 10.1074/Jbc.M109.010777 |
0.702 |
|
| 2009 |
Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handbook of Experimental Pharmacology. 341-66. PMID 19089336 DOI: 10.1007/978-3-540-68964-5_15 |
0.507 |
|
| 2009 |
Yoder AR, Barbieri KA, Robinson JW, Potter LR. Possible identification of novel natriuretic peptide receptor phosphorylation sites by alanine/glutamate mutagenesis Bmc Pharmacology. 9. DOI: 10.1186/1471-2210-9-S1-P76 |
0.742 |
|
| 2009 |
Yoder AR, Stone MD, Griffin T, Potter LR. Determination of new phosphorylation sites within natriuretic peptide receptors using mass spectrometric methods Bmc Pharmacology. 9. DOI: 10.1186/1471-2210-9-S1-P75 |
0.735 |
|
| 2009 |
Dickey DM, Yoder AR, Potter LR. ANP mutation causes reduced proteolysis Bmc Pharmacology. 9: P12. DOI: 10.1186/1471-2210-9-S1-P12 |
0.558 |
|
| 2008 |
Yoder AR, Kruse AC, Earhart CA, Ohlendorf DH, Potter LR. Reduced ability of C-type natriuretic peptide (CNP) to activate natriuretic peptide receptor B (NPR-B) causes dwarfism in lbab -/- mice. Peptides. 29: 1575-81. PMID 18554750 DOI: 10.1016/J.Peptides.2008.04.020 |
0.713 |
|
| Show low-probability matches. |